Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data (Q30622511)

16 August 2017

Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

16 August 2017

cardiovascular disease

1 reference

1 reference

1 reference

1 reference

A N Mavrogiannaki

1

1 reference

PMCID

3638654

16 August 2017

I N Migdalis

series ordinal

2

1 reference

16 August 2017

3 April 2013

1 reference

International journal of endocrinology

16 August 2017

1 reference

16 August 2017

2013

1 reference

16 August 2017

450639

1 reference

Creative Commons Attribution 3.0 Unported

16 August 2017

start time

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Potential of incretin-based therapies for non-alcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Pentoxifylline attenuates methionine- and choline-deficient-diet-induced steatohepatitis by suppressing TNF-α expression and endoplasmic reticulum stress

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Combination drug treatment in patients with non-alcoholic fatty liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Nonalcoholic fatty liver disease and the coronary artery disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Plasma metabolomic profile in nonalcoholic fatty liver disease.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Advanced MRI methods for assessment of chronic liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Nonalcoholic fatty liver disease in type 2 diabetes mellitus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Genes and nonalcoholic fatty liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Fatty liver: a novel component of the metabolic syndrome

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Genetics of alcoholic liver disease and nonalcoholic fatty liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Long-term follow-up of patients with NAFLD and elevated liver enzymes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Nonalcoholic fatty liver disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638654

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

20 June 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Effects of N-3 fatty acids on hepatic triglyceride content in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F450639

Statins and hepatic steatosis: perspectives from the Dallas Heart Study

21 January 2018

1 reference

12 December 2020

Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery

1 reference

12 December 2020

NASH predicts plasma inflammatory biomarkers independently of visceral fat in men

1 reference

12 December 2020

Natural history of NAFLD: remarkably benign in the absence of cirrhosis

1 reference

12 December 2020

Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty

1 reference

12 December 2020

The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

12 December 2020

Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies

1 reference

12 December 2020

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease

1 reference

12 December 2020

Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes

1 reference

12 December 2020

Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes

1 reference

12 December 2020

Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis

1 reference

12 December 2020

Identifiers

DOI

10.1155/2013/450639

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

PMCID

3638654